2007 Annual Meeting | Peripheral Neuropathy
09:00 AM - 09:50 AM |
Approach to the Peripheral Neuropathy Patient
Benn E. Smith, MD, FAAN |
|
09:50 AM - 10:40 AM |
Managing Peripheral Neuropathy Pain
Todd D. Levine, MD |
|
10:40 AM - 10:55 AM |
Break
|
|
10:55 AM - 11:20 AM |
Case Presentations and Panel Discussion
|
|
11:20 AM - 12:10 PM |
Guillain-Barre' Syndrome
Ted M. Burns, MD |
|
12:10 PM - 01:10 PM |
Lunch
|
|
01:10 PM - 02:00 PM |
Chronic Acquired Demyelinating Polyneuropathies
David S. Saperstein, MD |
|
02:00 PM - 02:25 PM |
Case Presentations and Panel Discussion
|
|
02:25 PM - 03:15 PM |
Controversial Entrapment Neuropathies
William W. Campbell, MD, MSHA, FAAN |
|
03:15 PM - 03:30 PM |
Case Presentations and Panel Discussion
|
|
03:30 PM - 03:45 PM |
Break
|
|
03:45 PM - 04:45 PM |
The Spectrum of Diabetic Peripheral Neuropathies
P. James B. Dyck, MD, FAAN |
|
04:45 PM - 05:00 PM |
Case Presentations and Panel Discussion
|
David S. Saperstein, MD | No disclosure on file |
Benn E. Smith, MD, FAAN | Dr. Smith has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Argenx. Dr. Smith has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for CSP Behring. |
Todd D. Levine, MD | Dr. Levine has received personal compensation for serving as an employee of CND life sciences . Dr. Levine has received personal compensation in the range of $100,000-$499,999 for serving as a Consultant for Nufactor. Dr. Levine has received personal compensation in the range of $50,000-$99,999 for serving as an Expert Witness for PNA. Dr. Levine has stock in CND Life Sciences. Dr. Levine has stock in Corinthian reference lab. |
P. James B. Dyck, MD, FAAN | Dr. Dyck has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Akcea/Ionis. |
William W. Campbell, MD, MSHA, FAAN | No disclosure on file |
Ted M. Burns, MD | Dr. Burns has nothing to disclose. |